Acute renal failure as the presenting sign of disseminated intravascular coagulation in a patient with metastatic prostate cancer

Ryuji Ohashi1
Yusuke Hosokawa2
Go Kimura3
Yukihiro Kondo3
Keiji Tanaka2
Shinichi Tsuchiya1

1Division of Diagnostic Pathology, 2Department of Intensive and Cardiac Care Unit, 3Department of Urology, Nippon Medical School, Tokyo, Japan

Correspondence: Ryuji Ohashi
Division of Diagnostic Pathology, Nippon Medical School, 1-1-5 Bunkyo-ku, Sendagi, Tokyo 113-8603, Japan
Tel +81 338 222 131
Fax +81 358 146 498
Email r-ohashi@nms.ac.jp

Abstract: Disseminated intravascular coagulation (DIC) is the most frequent coagulation disorder in patients with prostate cancer. However, renal involvement in DIC associated with prostate cancer has rarely been documented. Herein, we present a case of metastatic prostate cancer presenting with acute renal failure (RF) triggered by DIC. An 80 year old man with metastatic prostate cancer was treated with antihormone therapy at an outpatient clinic. He was admitted to our hospital because of severe dyspnea and progressive RF. A hemorrhagic tendency was not clinically evident. Laboratory tests exhibited a significant coagulation disorder, suggestive of DIC. Despite treatment, his RF and dyspnea worsened, and he eventually passed away. An autopsy study revealed hypertensive nephrosclerosis superimposed by fibrin rich thrombi formation involving glomerular capillaries and arterioles characteristic of DIC. Additionally, focal segmental glomerulosclerosis was identified, which was presumably secondary to the glomerular endothelial and/or podocyte injury augmented by DIC. Those findings showed that glomerular injury, which was induced and subsequently exacerbated by DIC associated with prostate cancer, highly contributed to the progression of RF in our case. A differential diagnosis of DIC should be considered when a patient with prostate cancer presents with renal dysfunction.

Keywords: disseminated intravascular coagulation, prostate cancer, renal pathology

Introduction

Disseminated intravascular coagulation (DIC) is the most frequent coagulation disorder in patients with prostate cancer.1 DIC occasionally occurs as a presenting sign of metastatic prostate cancer.2,3 Clinical symptoms of DIC associated with prostate cancer range from a subclinical marker of disease to overt bleeding after trauma or surgical procedures.3,4

Despite its frequent occurrence, little is known about the clinical presentation of DIC in prostate cancer. Specifically, renal involvement in DIC as a presenting sign has not been reported in the literature. In the present article, we describe an autopsy case of metastatic prostate cancer presenting with progressive renal dysfunction, which was augmented by DIC. We have described this case with emphasis on the renal histopathology characteristic of DIC, and include a brief review of the literature. This unusual case presentation demonstrates that DIC should be considered when prostate cancer patients present with renal dysfunction due to unknown etiology and therefore a comprehensive work up for DIC should be performed even in the absence of apparent hemorrhagic tendency.

Case presentation

An 80-year-old Japanese man was found to have increased serum prostate specific antigen levels of 231.5 ng/mL (normal: <1.0 ng/mL) on a routine medical checkup. He had
a long-standing history of hypertension and underwent a needle biopsy of the prostate gland that showed Gleason 4 + 5 = 9 adenocarcinoma. A computed tomography scan revealed that the tumor had invaded the bladder, and multiple metastatic lesions were found in the lumbar regions. He was started on a luteinizing hormone releasing hormone agonist (leuprolide) and androgen antagonist (flutamide), and was followed at an outpatient clinic. His serum creatinine levels were within a normal range (0.8–1.4 mg/dL) at this time.

The patient’s prostate specific antigen level increased to 1530 ng/mL 4 months later. A computed tomography scan revealed an increasing number of metastatic lesions in the lumbar bones. At this time, he complained of dyspnea that was probably due to pulmonary edema. His serum creatinine was 2.1 mg/dL. After 1 month, his dyspnea worsened as the renal failure progressed with a creatinine level of 2.89 mg/dL. A urine test showed strong presence of protein (++++) and occult blood (++). His serum total protein was 5.8 g/dL (normal: 6.0–8.3 g/dL), and his albumin was 2.3 g/dL (normal: 3.5–5.5 g/dL). He was admitted to the intensive care unit for further investigation and treatment.

Laboratory evaluation performed on the first day of intensive care unit admission revealed the following results: hemoglobin level, 10.2 g/dL; platelet count, 60 × 10^9/µL (normal: 150–400 × 10^9/µL); and total leukocyte count, 18.2 × 10^9/mm³ (normal: 4.0–11 × 10^9/mm³). His prothrombin time was 16.3 seconds (normal: 11.5–15.5 seconds), and his prothrombin time and international normalized ratio was 1.8 (normal: 1–1.25). The activated partial prothrombin time was 38.5 seconds (normal: 25.2–36 seconds); the serum fibrinogen level, 168 mg/dL (normal: 170–410 mg/dL); and D-dimer level, 28.8 µg/mL (normal: <1.0 µg/mL). His fibrin degradation product level was 93.9 µg/mL (normal: <10 µg/mL).

Although a bleeding tendency was not clinically evident, he was diagnosed with DIC based on the laboratory data. Treatment with antithrombin-III and blood transfusion was initiated. On the second day at the intensive care unit, he had oliguria associated with a serum creatinine level of 5.19 mg/dL, for which hemodialysis was started. His serum total protein was 5.1 g/dL, and his albumin level was 1.9 g/dL. The dyspnea progressively worsened despite treatment. His serum creatinine ranged from 4.5–5.0 mg/dL. Chest X-ray revealed pulmonary infiltrates in both lungs, which was suggestive of alveolar hemorrhage. On day 14, he experienced cardiac arrest and expired. An autopsy was performed which was suggestive of alveolar hemorrhage. On day 14, a chest X-ray revealed pulmonary infiltrates in both lungs.

Histopathology
Gross examination of the kidney revealed an irregular and roughly granular cortical surface, and there was marked congestive changes mainly involving the medulla. Microscopically, global glomerulosclerosis was noted in approximately 40% of all glomeruli. The arcuate and interlobular arteriolar walls showed moderate to severe thickening due to intimal fibrosis. These chronic glomerular and vascular alterations are reflective of hypertensive nephrosclerosis related to the patient’s long standing hypertension. The vast majority of the remaining glomeruli showed numerous thrombi formation mainly involving peripheral glomerular capillaries and afferent arterioles, reflective of severe coagulation disorder (Figure 1A and B). Some glomerular capillaries were distended by thrombi with features of thrombotic microangiopathic injury. A phosphotungstic acid hematoxylin stain identified dark blue fibrin strands constituting the thrombi (Figure 1C). CD41 immunostaining showed the presence of sparsely scattered platelets within the thrombi (Figure 1D). We believe that the formation of these thrombi under the condition of reduced nephrons due to nephrosclerosis highly contributed to progressive RF in this case.

In addition, focal segmental glomerulosclerosis (FSGS) was identified in 1% of nonglobally sclerotic glomeruli. The FSGS was characterized by segmental sclerosis of capillary architecture associated with attachment to Bowman’s capsule, accompanied by the prominence of overlying epithelial cells (Figure 1E). Another glomerulus exhibited the segmental obliteration of a few capillaries by infiltration of mononuclear leukocytes and foam cells, and attachment to Bowman’s capsule near the urinary pole (Figure 1F). Active lesions or thrombi formation were not evident in the interlobular or arcuate arteries.

In the lung, multiple foci of intra-alveolar hemorrhage in the background of diffuse edema with occasional thrombin formation were observed in the small to medium sized arteries. Adenocarcinoma was identified in the prostate with direct invasion into the bladder and multiple metastatic lesions involving the thoracic and lumbar vertebrae.

Discussion
DIC has been one of the most common complications of prostate cancer since the first report in 1953.¹ Clinical signs of DIC are noted in only 0.4%–1.65% of patients with prostate cancer, including a bleeding tendency.² In these patients, DIC can be triggered by surgical procedures like prostate biopsy causing hemorrhage in multiple sites, such as the skin, genitourinary organs, gastrointestinal tracts and
DIC represents the result of a widespread activation of the coagulation pathway. DIC proceeds from the simultaneous occurrence of systemic fibrin formation resulting from an increased generation of thrombi, impaired physiological anticoagulation mechanism, and inadequate fibrinolysis. The combination of increased formation and impaired removal of fibrin results in thrombotic occlusion of small and medium sized vessels. In cancer patients, tumor cells express a variety of procoagulant molecules including tissue factor and cancer procoagulant, which activate the host’s hemostatic system. Tumor cells also express fibrinolytic inhibitors such as plasminogen activator type 1, creating the hypofibrinolytic state that is characteristic of DIC. Proinflammatory cytokines, such as tumor necrosis factor α and interleukin-6, are also involved in DIC development.

Unfortunately, the underlying mechanism of DIC in prostate cancer has not been fully investigated and further studies are still needed. We expect that elucidation of the detailed mechanisms would enable us to invent new therapies and drugs to prevent the development of coagulation disorders in prostate cancer patients.

In our case, the most prominent histological finding was numerous thrombi within the glomerular capillary lumina and afferent arterioles. Furthermore, many afferent arterioles were occluded by thrombi, resulting in the collapse of the glomerular tufts, which is often called bloodless glomeruli. These vascular lesions are very similar to those of thrombocytopenic thrombotic purpura (TTP)/hemolytic uremic syndrome (HUS), which also occurs in prostate cancer. Despite the histological resemblance, major difference exists in the vascular lesions between DIC and TTP/HUS. In DIC, thrombi are fibrin rich, whereas TTP/HUS presents with platelet-rich thrombi. Clinically, TTP/HUS patients have normal platelet counts and prothrombin and D-dimer levels. This is in contrast to DIC, in which coagulation disorders are evident. In our case, the DIC diagnosis was established on the basis of abnormal laboratory data, such as low platelet count, prolonged prothrombin, and increased D-dimer and fibrin degradation product levels. This diagnosis was confirmed histologically by the presence of fibrin rich thrombi revealed by the phosphotungstic acid hematoxylin stain. Additionally, TTP/HUS can be reversible when properly treated whereas DIC is refractory to treatment and has a poor prognosis, which is consistent with the present case.

Another remarkable renal finding in our case was FSGS. FSGS is a pattern of glomerular injury that occurs as a primary form or as secondary to many conditions. The cause of primary FSGS is usually unknown, and patients often present with significant nephrotic syndrome, which was not identified in our case. In contrast, secondary forms of FSGS may be associated with a variety of conditions, including chronic hypertension, pyelonephritis, morbid obesity, and renal transplantation. A possible mechanism of secondary FSGS is a reduced number of nephrons, which increases glomerular pressure within remnant glomeruli and results in glomerular podocyte and/or endothelial injury. In our case, the patient appeared to have a reduced number of nephrons.

Figure 1 Renal pathology of DIC in association with metastatic prostate cancer. The peripheral glomerular capillaries (A) and afferent arteriole (B, arrows) were distented by thrombi formation (periodic acid methenamine silver stain). Fibrin strands revealed by phosphotungstic acid hematoxylin stain constituting the thrombi (C). The presence of sparsely scattered platelets within the thrombi was detected by immunostaining with an anti-CD41 antibody (D). Focal segmental sclerosis of the glomeruli (E and F; periodic acid methenamine silver stain). Segmental sclerosis of capillary architecture associated with attachments to the Bowman’s capsule with prominence of overlying epithelial cells (E, arrows). Segmental sclerosis was also noted at the urinary pole with capillary lumina obliterated by infiltration of mononuclear leukocytes and foam cells (F, arrowhead).

Notes: Original magnification: ×200. Scale bars: 100 μM.
due to hypertensive nephrosclerosis before the onset of DIC. We therefore speculate that the occurrence of DIC to the kidney with reduced nephrons may have augmented podocyte and/or endothelial injury of glomeruli, resulting in FSGS.

In summary, we have reported an autopsied patient who died of DIC associated with metastatic prostate cancer. This case was unique because acute RF was the initial presenting sign of DIC. We described clinicopathological aspects of DIC in prostate cancer and renal pathology of DIC along with a brief review of the literature. We propose that a differential diagnosis of DIC should be considered when a patient with prostate cancer presents with renal dysfunction and that complete physical and laboratory tests, including coagulation study, should be performed to detect a cause of renal dysfunction even in the absence of hemorrhagic tendency.

Acknowledgments
We express our appreciation to Mr Takenori Fujii for excellent technical assistance.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Smith JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology. 1999;54(Suppl 6A):8–14.
2. Duran I, Tannock IF. Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med. 2006;21(11):C6–C8.
3. Navarro M, Ruiz I, Martin G, Cruz JJ. Patient with disseminated intravascular coagulation and renal dysfunction in patients with metastatic cancer of the prostate. Risks of prostatic biopsy. Prostate Cancer Prostatic Dis. 2006;9(2):190–191.
4. Leong C, McKenzie MR, Coupland DB, Gascoyne RD. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy. J Nucl Med. 1994;35(10):1662–1664.
5. Tagnon HJ, Whitmore WF Jr, Schulman P, Kravitzi SC. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer. 1953;6(1):63–67.
6. Ruffion A, Manel A, Valignat C, Lopez JG, Perrin-Fayolle O, Perrin P. Successful use of Samarium 153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer. J Urol. 2000;164(3 Pt 1):782.
7. Al-Otaibi MF, Al-Taweel W, Bin-Saleh S, Herba M, Aprikian AG. Disseminated intravascular coagulation following transrectal ultrasound guided prostate biopsy. J Urol. 2004;171(1):346.
8. Hyman DM, Soff GA, Kampel LJ. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology. 2011;81(2):119–125.
9. Kampel LJ. Challenging problems in advanced malignancy: Case 2. Disseminated intravascular coagulation in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2003;21(16):3170–3171.
10. Levi M, de Jonge E, van der Poll T, ten Cate H. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Hemost. 2001;27(6):569–575.
11. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2(2):209–215.
12. Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost. 2008;34(2):143–145.
13. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2008;363–4:184–194.
14. Nakashima T, Tachibana M, Ueno M, Baba S, Tazaki H. Tumor necrosis factor and coagulopathy in patients with prostate cancer. Cancer Res. 1995;55(21):4881–4885.
15. Wada H, Tanigawa M, Wakita Y, et al. Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 1993;4(4):583–590.
16. Morel-Maroger L, Kanfer A, Solec K, Sraer JD, Richet G. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): clinicopathologic study in 20 adults. Kidney Int. 1979;15(3):548–558.
17. Müller NJ, Pestalozzi BC. Hemolytic uremic syndrome in prostatic carcinoma. Oncology. 1998;55(2):174–176.
18. Biers SM, Sullivan ME, Roberts IS, Noble JG. Thrombotic microangiopathy in advanced prostatic carcinoma. Urology. 2004;63(2):380–382.
19. Caramello V, Dovio A, Caraci P, Berrett A, Angeli A. Thrombotic thrombocytopenic purpura in advanced prostate cancer: case report and published work review. Int J Urol. 2007;14(2):150–152.
20. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38(5):469–479.
21. Kawasaki H, Hayashi K, Awa M. Disseminated intravascular coagulation (DIC). Immunohistochemical study of fibrin-related materials (FRMs) in renal tissues. Acta Pathol Jpn. 1987;37(1):77–84.
22. Burke AP, Mont E, Kolodgie F, Virmani R. Thrombotic thrombocytopenic purpura causing rapid unexpected death: value of CD61 immunohistochemical staining in diagnosis. Cardiovasc Pathol. 2005;14(3):150–155.
23. Park YA, Waldrum MR, Marques MB. Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. Am J Clin Pathol. 2010;133(3):460–465.
24. D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–2411.
25. Renkke HG, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis. 1989;13(6):443–456.
26. Cotran RS. Nephrology Forum. Glomerulosclerosis in reflux nephropathy. Kidney Int. 1982;21(3):528–534.
27. Warnke RA, Kempson RL. The nephritic syndrome in massive obesity: a study by light, immunofluorescence, and electron microscopy. Arch Pathol Lab Med. 1978;102(8):431–438.
28. Cossio FG, Franklin WL, Pelletier RP, Pesavento TE, Henry ML, Ferguson RM. Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. Am J Kidney Dis. 1999;34(4):731–738.
